CSL Limited is a global biotech leader in blood plasma therapies, vaccines (Seqirus) and iron-deficiency treatments. It trades on Australian Securities Exchange under the ticker CSL, in the Biotechnology sector.
Key Facts
| Item | Details |
|---|---|
| Ticker | CSL |
| Exchange | Australian Securities Exchange (CSL) |
| Sector | Biotechnology |
| Headquarters | Melbourne, Australia |
Bull Case & Risks
Bull Case
- A dominant plasma-therapies franchise
- High barriers to entry and scale
- A strong RandD pipeline
Risks
- Plasma-collection cost pressures
- Competition and pipeline risk
Outlook
CSL is a world-leading plasma-therapies and vaccines company with deep moats; the debate is plasma-collection economics and pipeline delivery.
Educational information only, not investment advice. Stocks carry risk including possible loss of principal; past performance does not guarantee future results.